title: Results of a phase II trial with cystemustine in advanced malignant melanoma. A trial of the EORTC Clinical Screening Group.
authors.forename: V
authors.initials: V
authors.lastname: Urosevic
authors.forename: P
authors.initials: P
authors.lastname: Chollet
authors.forename: A
authors.initials: A
authors.lastname: Adenis
authors.forename: J
authors.initials: J
authors.lastname: Chauvergne
authors.forename: P
authors.initials: P
authors.lastname: Fargeot
authors.forename: H
authors.initials: H
authors.lastname: Roche
authors.forename: P
authors.initials: P
authors.lastname: Kerbrat
authors.forename: M A
authors.initials: MA
authors.lastname: Lentz
authors.forename: P
authors.initials: P
authors.lastname: Fumoleau
authors.forename: B
authors.initials: B
authors.lastname: Chevallier
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000191:economics; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; C051263:N'-(2-chloroethyl)-N-(2-(methylsulfonyl)ethyl)-N'-nitrosourea